Value
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Fwd P/E | 2.5 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 45.6x
- ▸PEG: 0.37
- ▸Attractively valued
CADL · Why this verdict
Why Candel Therapeutics (CADL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts see roughly 106% upside from the current price, and the engine models a favorable 5.3x asymmetry ratio with about 79.5% modeled upside against 15% downside to stop-loss. Sentiment breakdown | The stock should close a meaningful portion of the gap to the analyst target over the next 12 months. | →Stable |
| CounterLight analyst coverage on a small biotech can produce an unreliable, overly optimistic consensus target that isn't grounded in near-term catalysts. | ||
The quality score of 1.5 sits well below the engine's 4.0 floor, driven by negative free cash flow and no competitive moat, typical of an early-stage biotech. Bear case | Quality score should stabilize or begin recovering above 4.0 as the company progresses toward revenue-generating milestones over the next 12 months. | →Stable |
| CounterCash burn and lack of a moat are structurally expected for a clinical-stage biotech and don't necessarily predict poor stock performance if trial data is positive. | ||
Short interest stands at 24% of float with implied volatility of 170%, both reflecting the market's expectation of a large, uncertain price move given the binary biotech risk profile. Key risks | Implied volatility should compress below 100% and short interest should decline over the next 12 months if uncertainty resolves favorably. | →Stable |
| CounterHigh short interest combined with a binary catalyst can also set up a large short squeeze on positive trial results, working in the opposite direction of the bearish positioning. | ||
The company has missed consensus estimates in three of its last four quarters, with an average surprise of about -5%, reflecting inconsistent quarter-to-quarter results typical of lumpy R&D spend. Earnings | The company should return to meeting or beating estimates in at least one of the next two quarters. | →Stable |
| CounterEPS estimates for pre-revenue biotechs are often based on modeled R&D burn rather than commercial performance, so misses may reflect timing of spend rather than business deterioration. | ||
Analysts see roughly 106% upside from the current price, and the engine models a favorable 5.3x asymmetry ratio with about 79.5% modeled upside against 15% downside to stop-loss.
→StableSentiment breakdown
- Expectation
- The stock should close a meaningful portion of the gap to the analyst target over the next 12 months.
CounterLight analyst coverage on a small biotech can produce an unreliable, overly optimistic consensus target that isn't grounded in near-term catalysts.
The quality score of 1.5 sits well below the engine's 4.0 floor, driven by negative free cash flow and no competitive moat, typical of an early-stage biotech.
→StableBear case
- Expectation
- Quality score should stabilize or begin recovering above 4.0 as the company progresses toward revenue-generating milestones over the next 12 months.
CounterCash burn and lack of a moat are structurally expected for a clinical-stage biotech and don't necessarily predict poor stock performance if trial data is positive.
Short interest stands at 24% of float with implied volatility of 170%, both reflecting the market's expectation of a large, uncertain price move given the binary biotech risk profile.
→StableKey risks
- Expectation
- Implied volatility should compress below 100% and short interest should decline over the next 12 months if uncertainty resolves favorably.
CounterHigh short interest combined with a binary catalyst can also set up a large short squeeze on positive trial results, working in the opposite direction of the bearish positioning.
The company has missed consensus estimates in three of its last four quarters, with an average surprise of about -5%, reflecting inconsistent quarter-to-quarter results typical of lumpy R&D spend.
→StableEarnings
- Expectation
- The company should return to meeting or beating estimates in at least one of the next two quarters.
CounterEPS estimates for pre-revenue biotechs are often based on modeled R&D burn rather than commercial performance, so misses may reflect timing of spend rather than business deterioration.
TrendMatrix Research · core thesis
Engine thesis — one sentence
CADL's outsized modeled analyst upside is weighed against a quality-floor breach, an inconsistent earnings track record, and elevated short interest reflecting the binary risk of a clinical-stage biotech.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| EPS growth | 10.0 |
Momentum
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 7.0 |
| OBV | 4.8 |
| MA position | 9.0 |
| Volume | 2.7 |
- ▸Overbought (RSI 78)
- ▸Above 200-day MA
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 4.4 |
- ▸Analyst upside: 105%
Insider
7.5/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.7 |
| growth rank | 5.0 |
Technical
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.8 |
| support resistance | 4.3 |
| 52w position | 7.4 |
| gap | 6.0 |
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.1 |
| days to cover | 3.3 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| debt equity | 8.6 |
- ▸High short interest justified: 24%
- ▸High IV: 292%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:5.5>=5.5
- ASYMMETRY:5.2>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:36d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
5.24
Upside
+78.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Growth at 10.0, Insider at 7.5, and Value at 7.2; the weakest are Quality at 1.5, Catalyst at 2.5, and Peer rank at 3.8. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 5.24 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Upside
Trip ifStock price falls more than 20% from the current $9.83 level within 12 months.
- P2Quality Floor Breach
Trip ifQuality score falls below 1.0 within the next 2 quarters.
- P3High Short Interest Elevated Iv
Trip ifImplied volatility falls below 100%, from the current 170%, within the next 6 months.
- P4Earnings Miss Pattern
Trip ifEPS surprise exceeds 0% (a beat) in 2 consecutive quarters.